Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Vvax001 in HPV-16 positive CIN3
2019-004050-29Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Vvax001 in cervical intraepithelial neoplasia (CIN), sponsored by University Medical Center Groningen. Primary endpoint: Clinical efficacy. Started Nov 2020; status: completed.
02
Drugs
Vvax001
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2019-004050-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004050-29.